Ratnakar Securities Pvt. Ltd.

BAL PHARMA LTD.

NSE : BALPHARMABSE : 524824ISIN CODE : INE083D01012Industry : Pharmaceuticals & DrugsHouse : Private

BSE105.801.32 (+1.26 %)

PREV CLOSE ( ) 104.48

OPEN PRICE ( ) 108.25

BID PRICE (QTY) 106.75 (50)

OFFER PRICE (QTY) 107.44 (48)

VOLUME 4059

TODAY'S LOW / HIGH ( )103.40 108.25

52 WK LOW / HIGH ( )76.3 157.9

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987

Management Info

- Chairman Shailesh Siroya - Managing Director

Registered Office

Address #21&22, Bommasandra Industrial Area,Anekal Taluk, ,
Bengaluru,
Karnataka-560099

Phone 080 41570811 / 13 / 19

Email investor@balpharma.com

Website www.balpharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C-101, 1st Floor,247 Park, Lal Bahadur Shastri Marg,Vikhroli West,Mumbai

Listing : BSE, NSE

NEWS

05Nov Bal Pharma informs about board meeting
Bal Pharma has informed that the meeting of the Board of Directors of th..

30Aug Bal Pharma informs about annual report
Bal Pharma has informed that it enclosed the unabridged Annual Report of..

04Apr BAL Pharma informs about compliance ce
BAL Pharma has submitted confirmation as prescribed under the Regulation..

02Apr Bal Pharma informs about non-applicabi
Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 da..

14Feb Bal Pharma informs about press release
Bal Pharma has informed that it enclosed copies of the newspaper adverti..

Financials

in Millions

	QTR Dec 24	ANNUAL 24
Net Profit	11.5499999999999	102.72
Gross Profit	12.0299999999999	121.06
Operating Profit	85.4599999999999	357.93
Net Sales	728.85	3385.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 11667.80 (6.62%)	M.Cap ( in Cr)14882.67
Abbott India (BSE) 29550.00 (1.42%)	M.Cap ( in Cr)62828.02
Astrazeneca Pharma I (BSE) 8349.15 (3.99%)	M.Cap ( in Cr)20828.13
Divi's Lab (BSE) 5569.00 (3.44%)	M.Cap ( in Cr)148427.47
Caplin Point Lab (BSE) 1829.75 (6.59%)	M.Cap ( in Cr)14069.76

Shareholding Pattern

	PROMOTERS	50.86%
	NON-INSTITUTION	49%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

BAL PHARMA LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES